SCHEMBL4478273

SCHEMBL4478273

CCOC(=O)c1ncc(O)c2c1CCN(Cc1ccc(OC)cc1)C2=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
EGLN1 Q9GZT9 4/20 0.42
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42
TUBB8 Q3ZCM7 1/20 0.42
TUBA3E Q6PEY2 1/20 0.42
TUBA1A Q71U36 1/20 0.42
TUBA1C Q9BQE3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6032420 1.00 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1L3MBTL1SMN1; SMN2
SCHEMBL2728496 0.90 EGLN1 (0.44) ALDH1A1KMT2AMEN1L3MBTL1SMN1; SMN2
SCHEMBL4484374 0.89 LMNA (0.49) ALDH1A1KMT2AMEN1L3MBTL1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL4499510 0.85 LMNA (0.46) ALDH1A1KMT2AMEN1L3MBTL1SMN1; SMN2
SCHEMBL1336916 0.84 MEN1 (0.42) ALDH1A1KMT2AMEN1L3MBTL1SMN1; SMN2
SCHEMBL4477132 0.82 LMNA (0.50) ALDH1A1KMT2AMEN1L3MBTL1SMN1; SMN2
SCHEMBL4487206 0.81 MEN1 (0.49) ALDH1A1KMT2AMEN1L3MBTL1SMN1; SMN2
SCHEMBL10233993 0.79 ALDH1A1 (0.43) ALDH1A1KMT2AMEN1SMN1; SMN2CYP1A2
SCHEMBL4492762 0.78 EGLN1 (0.47) ALDH1A1KMT2AMEN1SMN1; SMN2CYP1A2
SCHEMBL1336853 0.78 P2RX7 (0.42) ALDH1A1KMT2AMEN1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP disclosed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO disclosed
WO-2005087767-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H ALDH1A1 1500/4885KMT2A 1470/4885MEN1 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.